Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
BioMarin Pharmaceutical raised 2025 revenue guidance on strong product sales and a $4.8B accretive Amicus acquisition, supported by FDA regulatory catalysts and an 18% stock gain over 3 weeks, validating near-term positive momentum.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Profitability Decline ⢠Leverage Surge ⢠Liquidity Erosion BMRN retains solid margins and cash generation, but sharply weaker profitability, deteriorating liquidity, debt-funded expansion, and elevated valuation warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Defended mid-$60s ⢠Neutral momentum ⢠Breakout pending Support Level: $64.70â$65.20 Resistance Level: $67.70â$69.30 BMRN is cautiously constructive over the last month, holding above $64.70â$65.20 support but needing a break above $67.70â$69.30 to confirm upside momentum.
Sentiment & News
Key News Insights: ⢠Earnings Beat ⢠Raised Guidance ⢠Pipeline Expansion BioMarin's earnings beat, raised guidance, acquisitions, and patent settlement strengthen its rare-disease growth outlook.
AI Summary
BioMarin's shift into a leveraged rare-disease consolidator broadens growth beyond VOXZOGO, but at a rich valuation investors should require clear evidence that acquired-product synergies and sustained VOXZOGO demand convert into margin expansion and rapid deleveraging.
Description
BioMarin Pharmaceutical is a biopharmaceutical company that develops and sells therapies for rare and serious genetic and metabolic disorders, with marketed treatments across lysosomal storage disorders, phenylketonuria, Batten disease, achondroplasia and related conditions. Its late-stage pipeline includes gene therapies for hemophilia A and phenylketonuria and early-stage programs for primary hyperoxaluria, while commercial operations distribute products through specialty pharmacies, hospitals and wholesalers in the U.S., Europe, Latin America and other markets. The company maintains multiple licensing and collaboration arrangements and is headquartered in San Rafael, California, having been founded in 1996.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 22 | Dec 29 | BMRN | BioMarin Pharmaceutical Inc. | BioMarin Pharmaceutical raised 2025 revenue guidance on strong product sales and a $4.8B accretive Amicus acquisition, supported by FDA regulatory catalysts and an 18% stock gain over 3 weeks, validating near-term positive momentum. | Closed | +1.3% |